Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Urology
Published in: BMC Urology 1/2018

Open Access 01-12-2018 | Research article

Changes in the outcome of prostate biopsies after preventive task force recommendation against prostate-specific antigen screening

Authors: Ahmed S. Zakaria, Alice Dragomir, Fadi Brimo, Wassim Kassouf, Simon Tanguay, Armen Aprikian

Published in: BMC Urology | Issue 1/2018

Login to get access

Abstract

Background

The benefits of PSA-based screening for prostate cancer (PCa) are controversial. The Canadian and American Task Forces on Preventive Health Care (CTFPHC & USPSTF) have released recommendations against the use of routine PSA-based screening for any men. We thought to assess the impact of these recommendations on the outcomes and trends of prostate needle biopsies.

Methods

A complete chart review was conducted for all men who received prostate needle biopsies at McGill University Health Center between 2010 and 2016. Of those, we included 1425 patients diagnosed with PCa for analysis. We Compared 2 groups of patients (pre and post recommendations’ release date) using Welch’s t-tests and Chi-square test. A multivariate logistic regression model was used to analyze variables predicting worse pathological outcomes.

Results

When the release date of the USPSTF draft (October 2011) was used as a cut-off, we found an average annual decrease of 10.6% in the total number of biopsies. The median (IQR) baseline PSA levels were higher in post-recommendations group (n = 977) when compared to pre-recommendations group (n = 448) [8 ng/ml (5.7–12.9) versus 6.4 ng/ml (4.9–10.1), respectively. P = 0.0007]. Also, post-recommendations group’s patients had higher Gleason score (G7: 35.4% versus 28.4% and G8-G10: 31.2% versus 18.1%, respectively. P < 0.0001). Moreover, they had higher intermediate and high-risk PCa classification (36.4% versus 32.8% and 35.5% versus 22.1%, respectively. P < 0.0001). The recommendations release date was an independent variable associated with higher Gleason score in prostate biopsies (OR: 2.006, 95%CI: 1.477–2.725). Using the CTFPHC recommendations release date (October 2014) as a cut-off in further analysis, revealed similar results.

Conclusions

Our results revealed a reduction in the number of prostate needle biopsies performed over time after the recommendations of the preventive task forces. Furthermore, it showed a significant relative increase in the higher risk PCa diagnosis. The oncological outcomes associated with this trend need to be examined in further studies.
Literature
1.
2.
Canadian Cancer Society’s Advisory. Committee on Cancer Statistics. Canadian Cancer Statistics 2016. Toronto, : Canadian Cancer society 2016. October 2016.
3.
Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317(15):909–16.CrossRefPubMed
4.
Stanford JL, Stephenson RA, Coyle LM, Cerhan J, Correa R, Eley J, et al. SEER program, National Cancer Institute. NIH pub. 1973–1995;1999(99–4543)
5.
6.
Andriole GL, Crawford ED, Grubb RL III, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310–9.CrossRefPubMedPubMedCentral
7.
Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320–8.CrossRefPubMed
8.
Andriole GL, Crawford ED, Grubb RL III, Buys SS, Chia D, Church TR, et al. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian Cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104(2):125–32.CrossRefPubMedPubMedCentral
9.
Force UPST. Screening for prostate cancer: US preventive services task force recommendation statement. Ann Intern Med. 2008;149(3):185.CrossRef
10.
Moyer VA. Screening for prostate cancer: US preventive services task force recommendation statement. Ann Intern Med. 2012;157(2):120–34.CrossRefPubMed
11.
Shoag J, Halpern JA, Lee DJ, Mittal S, Ballman KV, Barbieri CE, et al. Decline in prostate Cancer screening by primary care physicians: an analysis of trends in the use of digital rectal examination and prostate specific antigen testing. J Urol. 2016;196(4):1047–52.CrossRefPubMed
12.
Drazer MW, Huo D, Eggener SE. National Prostate Cancer Screening Rates after the 2012 US preventive services task force recommendation discouraging prostate-specific antigen-based screening. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(22):2416–23.CrossRef
13.
Jemal A, Fedewa SA, Ma J, Siegel R, Lin CC, Brawley O, et al. Prostate Cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA. 2015;314(19):2054–61.CrossRefPubMed
14.
Sammon JD, Abdollah F, Choueiri TK, Kantoff PW, Nguyen PL, Menon M, et al. Prostate-specific antigen screening after 2012 US preventive services task force recommendations. JAMA. 2015;314(19):2077–9.CrossRefPubMed
15.
D'amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969–74.CrossRefPubMed
16.
17.
Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. The lancet oncology. 2010;11(8):725–32.CrossRefPubMedPubMedCentral
18.
Tasian GE, Cooperberg MR, Cowan JE, Keyashian K, Greene KL, Daniels NA, et al., editors. Prostate specific antigen screening for prostate cancer: knowledge of, attitudes towards, and utilization among primary care physicians. Urologic Oncology: Seminars and Original Investigations; 2012: Elsevier.
19.
Hutchinson R, Akhtar A, Haridas J, Bhat D, Roehrborn C, Lotan Y. Testing and referral patterns in the years surrounding the US preventive services task force recommendation against prostate-specific antigen screening. Cancer. 2016;122(24):3785–93.CrossRefPubMed
20.
Rahbar H, Karabon P, Menon M, Trinh Q-D, Abdollah F. Trends in Prostate-Specific Antigen Screening Since the Implementation of the 2012 US preventive services task force recommendations. European Urology Focus 2017.
21.
Gaylis FD, Choi JE, Hamilton Z, Dato P, Cohen E, Calabrese R, et al., editors. Change in prostate cancer presentation coinciding with USPSTF screening recommendations at a community-based urology practice. Urologic Oncology: Seminars and Original Investigations; 2017: Elsevier.
22.
Bhindi B, Mamdani M, Kulkarni GS, Finelli A, Hamilton RJ, Trachtenberg J, et al. Impact of the U.S. preventive services task force recommendations against prostate specific antigen screening on prostate biopsy and cancer detection rates. J Urol. 2015;193(5):1519–24.CrossRefPubMed
23.
Banerji JS, Wolff EM, Massman JD, Odem-Davis K, Porter CR, Corman JM. Prostate needle biopsy outcomes in the era of the US preventive services task force recommendation against prostate specific antigen based screening. J Urol. 2016;195(1):66–73.CrossRefPubMed
24.
Gershman B, Van Houten HK, Herrin J, Moreira DM, Kim SP, Shah ND, et al. Impact of prostate-specific antigen (PSA) screening trials and revised PSA screening guidelines on rates of prostate biopsy and postbiopsy complications. Eur Urol. 2017;71(1):55–65.CrossRefPubMed
25.
Halpern JA, Shoag JE, Artis AS, Ballman KV, Sedrakyan A, Hershman DL, et al. National Trends in prostate biopsy and radical prostatectomy volumes following the US preventive services task force guidelines against prostate-specific antigen screening. JAMA surgery. 2017;152(2):192–8.CrossRefPubMed
26.
Misra-Hebert AD, Hu B, Klein EA, Stephenson A, Taksler GB, Kattan MW, et al. Prostate cancer screening practices in a large, integrated health system: 2007–2014. BJU Int. 2017;
27.
Hu JC, Nguyen P, Mao J, Halpern J, Shoag J, Wright JD, et al. Increase in prostate cancer distant metastases at diagnosis in the United States. JAMA oncology. 2017;3(5):705–7.CrossRefPubMed
28.
Barocas DA, Mallin K, Graves AJ, Penson DF, Palis B, Winchester DP, et al. Effect of the USPSTF grade D recommendation against screening for prostate cancer on incident prostate cancer diagnoses in the United States. J Urol. 2015;194(6):1587–93.CrossRefPubMed
29.
Jemal A, Ma J, Siegel R, Fedewa S, Brawley O, Ward EM. Prostate cancer incidence rates 2 years after the US preventive services task force recommendations against screening. JAMA oncology. 2016;2(12):1657–60.CrossRefPubMed
30.
Force USPST. Screening for prostate cancer: us preventive services task force recommendation statement. JAMA. 2018;319(18):1901–13.CrossRef
Metadata
Title
Changes in the outcome of prostate biopsies after preventive task force recommendation against prostate-specific antigen screening
Authors
Ahmed S. Zakaria
Alice Dragomir
Fadi Brimo
Wassim Kassouf
Simon Tanguay
Armen Aprikian
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2018
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/s12894-018-0384-x

Other articles of this Issue 1/2018

BMC Urology 1/2018 Go to the issue

Research article

Pre- and intra-operative predictors of postoperative hospital length of stay in patients undergoing radical prostatectomy for prostate cancer in China: a retrospective observational study

Research article

Predicting 90-day and long-term mortality in octogenarians undergoing radical cystectomy

Research article

Perineural invasion as an independent predictor of biochemical recurrence in prostate cancer following radical prostatectomy or radiotherapy: a systematic review and meta-analysis

Research article

Efficacy analysis of self-help position therapy after holmium laser lithotripsy via flexible ureteroscopy

Research article

Risk factors for urinary tract infection in patients with urolithiasis—primary report of a single center cohort

Review

Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion